Alex Zhavoronkov, PhD

Alex Zhavoronkov, PhD

Creator
0 followers

Insilico Medicine founder; posts AI drug discovery and aging research developments.

Google's Mac Codex Release Crucial for Future Dominance
SocialApr 24, 2026

Google's Mac Codex Release Crucial for Future Dominance

If @Google does not release their own version of Codex on Mac in the next 90 days, they will lose the game. If they do, they may become the world's most valuable company

By Alex Zhavoronkov, PhD
AI-Driven Drug Discovery Beats Billion‑Dollar AI Acquisitions
SocialApr 22, 2026

AI-Driven Drug Discovery Beats Billion‑Dollar AI Acquisitions

This is interesting. Just when I thought that Cursor was slaughtered by Claude and Codex, @SpaceX wants to buy them for $60 Billion. For $60 Billion, I can probably make the astronauts more resistant to radiation with potent radioprotectors...

By Alex Zhavoronkov, PhD
Insilico Tops AI Drug Discovery, Drives Oncology Breakthroughs
SocialApr 22, 2026

Insilico Tops AI Drug Discovery, Drives Oncology Breakthroughs

I had to skip this year's #AACR2026 but I am watching it from the distance. Our posters and team did a very good job - it looks like our clinical-stage oncology assets are finally being better understood by the pharma...

By Alex Zhavoronkov, PhD
World's First Longevity Board Launched to Accelerate Aging Therapies
SocialApr 21, 2026

World's First Longevity Board Launched to Accelerate Aging Therapies

I am very happy to report that we formed the world's first Longevity Board at the public biotechnology company. Our objective is to discover and develop longevity therapeutics with pipeline-in-a-product potential. GLP-1 therapeutics paved the way and demonstrated the path...

By Alex Zhavoronkov, PhD
AI-Driven Medicine and Cars to Extend Productive Life
SocialApr 21, 2026

AI-Driven Medicine and Cars to Extend Productive Life

Extending human productive life and restoring lost function should be the ultimate objective of AI-powered discovery medicine. It was a great pleasure to share some the story, current progress and long-term plans at one of the most impactful events of...

By Alex Zhavoronkov, PhD
Biotech Must Prioritize Collaboration, Not Nationalism, for Patients
SocialApr 20, 2026

Biotech Must Prioritize Collaboration, Not Nationalism, for Patients

After a week in Washington DC at one of the best new annual events by @semafor , I came to China for just 2 nights to meet some of my friends from Washington. I even had to skip this year's...

By Alex Zhavoronkov, PhD
AI-Driven Drug Discovery: Current Landscape and Future Promise
SocialApr 20, 2026

AI-Driven Drug Discovery: Current Landscape and Future Promise

Cool review and perspective on the current state and the future of AI-powered drug discovery https://t.co/AgwqOlt4RU

By Alex Zhavoronkov, PhD
AI-Optimized Molecules Drive Clinical Interest and Expansion
SocialApr 19, 2026

AI-Optimized Molecules Drive Clinical Interest and Expansion

#AACR2026 is in full swing and our posters are very popular. And some pharma companies realized that we have clinical data now and the molecules were AI-optimized to avoid the common liabilities. Finally, some genuine interest and we will have...

By Alex Zhavoronkov, PhD
R&D Hype Unchecked: No Accountability for Drug Promises
SocialApr 18, 2026

R&D Hype Unchecked: No Accountability for Drug Promises

Nice article by @TClozel in @FastCompany. Link in comments. The funny thing is that every company he mentioned and many others promised many years ago and still promise cheaper, faster, higher PoS drugs and many of them do not...

By Alex Zhavoronkov, PhD
AI Pharma Success Measured by Speed, Cost, Not Approvals
SocialApr 17, 2026

AI Pharma Success Measured by Speed, Cost, Not Approvals

Very often I am being asked when will the first drugs designed using AI receive regulatory approval. The answer is very simple - there are several drugs that were already approved. For example, the first antibody to receive regulatory approval...

By Alex Zhavoronkov, PhD
Demanding 1,200 Benchmark Test Before Claiming SOTA
SocialApr 17, 2026

Demanding 1,200 Benchmark Test Before Claiming SOTA

Until they test it in @InSilicoMeds benchmarks (1,200 benchmarks), I will not believe that this is anywhere close to SOTA. Let's benchmark it folks. Whoever has access and would like to benchmark - let's collaborate

By Alex Zhavoronkov, PhD
Chinese Pharma Leads Speed, Insilico Wins on Novelty
SocialApr 17, 2026

Chinese Pharma Leads Speed, Insilico Wins on Novelty

Very insightful article in China Daily. There is a big delta between the AI CRO model and AI Biotech model. At Insilico, we do not compete with Xtalpi or other local companies. The most hardcore competitors now are the large...

By Alex Zhavoronkov, PhD
AI‑Driven Trials Could Propel India’s Pharma Leaders
SocialApr 17, 2026

AI‑Driven Trials Could Propel India’s Pharma Leaders

One of the most amazing encounters at Semafor World Economy was with Satish Reddy of Dr. @bindureddy's Laboratories , the largest or second largest pharma company in India, depending on how you look at it. Now, they are also looking...

By Alex Zhavoronkov, PhD
AI-Driven Precision Oncology Breakthrough From Korean Researchers
SocialApr 15, 2026

AI-Driven Precision Oncology Breakthrough From Korean Researchers

One unexpected but very insightful paper in Nature BJC from a leading institution in Korea on precision oncology and AI-driven drug discovery. I read it with great pleasure and you should read it too. https://t.co/vpxofjt9Mn https://t.co/SXs4n72CcY

By Alex Zhavoronkov, PhD